COVID-19 Collection

Journal article

A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®

Abstract:: ClinicalTrials.gov NCT04805125 . Registered on March 18, 2021.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Share
Cite

Cite this record

APA Style

Speich, B., Chammartin, F., Smith, D., Stoeckle, M. P., Amico, P., Eichenberger, A. L., Hasse, B., Schuurmans, M. M., Müller, T., Tamm, M., Dickenmann, M., Abela, I. A., Trkola, A., Hirsch, H. H., Manuel, O., Cavassini, M., Hemkens, L. G., Briel, M., Mueller, N. J., … Kusejko, K. (2021). A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®. Trials, 22(1), 724–724.

MLA Style

Speich, B, et al. “A Trial Platform to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: First Sub-Protocol for a Pilot Trial Comparing the MRNA Vaccines Comirnaty® and COVID-19 MRNA Vaccine Moderna®.” Trials, vol. 22, no. 1, 2021, pp. 724–24.

Chicago Style

Speich, B, F Chammartin, D Smith, et al. 2021. “A Trial Platform to Assess Approved SARS-CoV-2 Vaccines in Immunocompromised Patients: First Sub-Protocol for a Pilot Trial Comparing the MRNA Vaccines Comirnaty® and COVID-19 MRNA Vaccine Moderna®.” Trials 22 (1): 724–24.
Print

Access Document

Files:: Speich_et_al_2021_A_trial_platform.pdf

(Preview, Version of record, pdf, 668.4KB, Terms of use)

Publisher copy:: 10.1186/s13063-021-05664-0

Publication website:: https://www.zora.uzh.ch/id/eprint/275961/1/journal.pone.0317965.pdf

Authors

+ Speich, B More by this author

Institution:: University of Oxford
Role:: Author
ORCID:: 0000-0002-3301-8085

+ Chammartin, F More by this author

Role:: Author
ORCID:: 0000-0001-8959-2724

+ Smith, D More by this author

Role:: Author
ORCID:: 0009-0002-8283-3227

+ Stoeckle, MP More by this author

Role:: Author
ORCID:: 0000-0002-0088-5078

+ Amico, P More by this author

Role:: Author

More authors...

+ Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung More from this funder

Funder identifier:: 10.13039/501100001711
Grant:: Project ID:196245

Publisher:: BioMed Central
Journal:: Trials More from this journal
Volume:: 22
Issue:: 1
Pages:: 724-724
Article number:: 724
Publication date:: 2021-10-21
DOI:: 10.1186/s13063-021-05664-0
EISSN:: 1745-6215
ISSN:: 1745-6215

Language:: English
Keywords:: Immunology

Medicine

Pathology

Clinical trial

Vaccination

Internal medicine

Cohort

Vaccine trial

Protocol (science)

Vaccine efficacy

Alternative medicine

Coronavirus disease 2019 (COVID-19)

Disease

Pandemic

Randomized controlled trial
Pubs id:: 1206202
Local pid:: pubs:1206202
Source identifiers:: W3197222415
Deposit date:: 2026-03-26
ARK identifier:: ark:/29072/ora_47a7b2f470104de8a659c3f0460cee27

Terms of use

Copyright date:: 2021

Licence:: CC Attribution (CC BY)

Views and Downloads

About views and downloads

If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP